Radiation-induced xerostomia in patients with head and neck cancer: Pathogenesis, impact on quality of life, and management

Head and Neck

Volumn 26, Issue 9, 2004, Pages 796-807

  Chambers, Mark S ^a   Garden, Adam S ^a   Kies, Merrill S ^a   Martin, Jack W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Dry mouth; Radiation therapy; Salivary glands; Sialogogues; Xerostomia

Indexed keywords

ANOREXIGENIC AGENT; ANTI ACNE AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BETHANECHOL; BRONCHODILATING AGENT; CEVIMELINE; CHLORHEXIDINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DECONGESTIVE AGENT; DIURETIC AGENT; MUSCARINIC AGENT; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; PILOCARPINE; POVIDONE IODINE; SALIVA SUBSTITUTE; SEDATIVE AGENT; SPASMOLYTIC AGENT; TETRACYCLINE; UNINDEXED DRUG;

ACUTE DISEASE; ANTIBIOTIC PROPHYLAXIS; ASTHMA; AUTOTRANSPLANTATION; BONE NECROSIS; CANCER RADIOTHERAPY; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENTAL CARE; DENTAL CARIES; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOSIMETRY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DYSPHAGIA; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; HYPERHIDROSIS; INTENSITY MODULATED RADIATION THERAPY; MOUTH HYGIENE; MOUTH INFECTION; MOUTH ULCER; MUCOSA INFLAMMATION; NASOPHARYNX CANCER; NAUSEA; NONHUMAN; OROPHARYNX CANCER; PAROTID GLAND; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RADIATION INJURY; RADIATION NECROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; SALIVARY GLAND; SALIVATION; SCORING SYSTEM; SIALOADENITIS; SJOEGREN SYNDROME; SPEECH; SUBMANDIBULAR GLAND; SWALLOWING; SWEATING; SYMPTOMATOLOGY; TASTE DISORDER; TOOTH BRUSHING; TREATMENT PLANNING; XEROSTOMIA;

HEAD AND NECK NEOPLASMS; HUMANS; QUALITY OF LIFE; RADIOTHERAPY; SALIVARY GLANDS; SALIVATION; XEROSTOMIA;

EID: 4344691765     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.20045     Document Type: Review

References (73)

1. Shaha AR, Patel S, Shasha D, Harrison LB. Head and neck cancer. In: Lenhard RE Jr, Osteen RT, Gansler T, editors. Clinical oncology. Atlanta, Ga: American Cancer Society; 2001. p 297-330.
2. Criswell MA, Sinha CK. Hyperthermic, supersaturated humidification in the treatment of xerostomia. Laryngoscope 2001;111:992-996.
3. Mercadante S, Calderone L, Villari P, et al. The use of pilocarpine in opioid-induced xerostomia. Palliat Med 2000; 14:529-531.
4. Peterson DE. Oral problems in supportive care: no longer an orphan topic? Support Care Cancer 2000;8:347-348.
5. Seikaly H, Jha N, McGaw T, Coulter L, Liu R, Oldring D. Submandibular gland transfer: a new method of preventing radiation-induced xerostomia. Laryngoscope 2001;111: 347-352.
6. Davies AN, Broadley K, Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage 2001;22:820-825.
7. Narhi TO. Prevalence of subjective feelings of dry mouth in the elderly. J Dent Res 1994;73:20-25.
8. Schiodt M. HIV-associated salivary gland disease: a review. Oral Surg Oral Med Oral Pathol 1992;73:164-167.
9. Sreebny LM, Valdini A, Yu A. Xerostomia. Part II: relationship to nonoral symptoms, drugs, and diseases. Oral Surg Oral Med Oral Pathol 1989;68:419-427.
10. Kao CH, Tsai SC, Sun SS. Scintigraphic evidence of poor salivary function in type 2 diabetes. Diabetes Care 2001; 24:952-953.
11. Nicolatou-Galitis O, Kitra V, Vliet-Constantinidou C, et al. The oral manifestations of chronic graft-versus-host disease (cGVHD) in paediatric allogeneic bone marrow transplant recipients. J Oral Pathol Med 2001;30:148-153.
12. Kies MS, Haraf DJ, Rosen F, et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 2001;19:1961-1969.
13. Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression, and stress. J Dent Res 2000; 79:1652-1658.
14. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-705.
15. California Dental Hygienists Association. Xerostomia: drymouth. Available at: http://www.cdha.org/articles/drymouth.htm. Accessed February 7, 2003.
16. Sjogren R, Nordstrom G. Oral health status of psychiatric patients. J Clin Nurs 2000;9:632-638.
17. Nagler RM, Gez E, Rubinov R, et al. The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma. Arch Oral Biol 2001;46:487-493.
18. Logemann JA, Smith CH, Pauloski BR, et al. Effects of xerostomia on perception and performance of swallow function. Head Neck 2001;23:317-321.
19. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-704.
20. Jellema AP, Langendijk H, Bergenhenegouwen L, et al. The efficacy of Xialine in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiother Oncol 2001;59:157-160.
21. Leek H, Albertsson M. Pilocarpine treatment of xerostomia in head and neck patients. Micron 2002;33:153-155.
22. Reddy SP, Leman CR, Marks JE, Emami B. Parotid-sparing irradiation for cancer of the oral cavity: maintenance of oral nutrition and body weight by preserving parotid function. Am J Clin Oncol 2001;24:341-346.
23. Berger AM, Kilroy TJ. Oral complications of cancer therapy. In: Berger AM, Portenoy RK, Weissman DE, editors. Principles and practice of supportive oncology. Philadelphia: Lippincott-Raven Publishers; 1998. p 223-236.
24. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346.
25. Trotti A, Colevas D, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
26. Common Terminology Criteria for Adverse Events v3.0 (CTCAE): http://ctep.cancer.gov/forms/CTCAEv3.pdf; published December 12, 2003.
27. Chambers MS, Keene HJ, Toth BB, Martin CG, Payne R, Gallagher SC. Mutans Streptococci in xerostomic cancer patients after pilocarpine therapy. J Dent Res 81, Special Issue A (IADR/AADR Abstract 3609); 443, March 2002.
28. Chambers MS, Toth BB, Martin JW, Fleming TJ, Lemon JC. Oral and dental management of the cancer patient; patient: prevention and treatment of complications. Support Care Cancer 1995;3:168-175.
29. Slavkin HC, Baum BJ. Relationship of dental and oral pathology to systemic illness. JAMA 2000;284:1215-1217.
30. Spielman AI. Interaction of saliva and taste. J Dent Res 1990;69:838-843.
31. Hughes PJ, Scott PM, Kew J, et al. Dysphagia in treated nasopharyngeal cancer. Head Neck 2000;22:393-397.
32. Harrison LB, Zelefsky MJ, Pfister DG, et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck 1997;19:169-175.
33. Epstein JB, Emerton S, Kolbinson DA, et al. Quality of life and oral function following radiotherapy for head and neck cancer. Head Neck 1999;21:1-11.
34. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 2001;23:389-398.
35. Schubert MM, Peterson DE, Lloid ME. Oral complications. In: Thomas EDBKG, Forman SJ, editors. Hematopoietic cell transplantation. 2nd ed. Malden, Ma: Blackwell Science Inc.; 1999. p 751-763.
36. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999;17:3333-3355.
37. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 2000;57:113-118.
38. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339-3345.
39. Fleming TJ, Rambach SC. A tongue-shielding radiation stent. J Prosthet Dent 1983;49:389-392.
40. Kaanders JHAM, Fleming TJ, Ang KK, Maor MH, Peters LJ. Devices valuable in head and neck radiotherapy. Int J Radiat Oncol Biol Phys 1992;23:639-645.
41. O'Sullivan B, Warde P, Grice B, et al. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillarregion. Int J Radiat Oncol Biol Phys 2001;51:332-343.
42. Webb S. IMRT: general considerations. In: Webb S, editor. Intensity-modulated radiation therapy. Philadelphia: Institute of Physics Publishing; 2001. p 1-34.
43. Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2000; 48:711-722.
44. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001;49:907-916.
45. Chao KS, Majhail N, Huang CJ, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001;61:275-280.
46. Spiegel JH, Deschler DG, Cheney ML. Microvascular transplantation and replantation of the rabbit submandibular gland. Arch Otolaryngol Head Neck Surg 2001; 127:991-996.
47. Spiegel JH, Zhang F, Levin DE, Singer MI, Buncke HJ. Microvascular transplantation of the rat submandibular gland. Plast Reconstr Surg 2000;106:1326-1335.
48. Greer JE, Eltorky M, Robbins KT. A feasibility study of salivary gland autograft transplantation for xerostomia. Head Neck 2000;22:241-246.
49. Nagler RM, Baum BJ. Treatment reduces the severity of xerostomia following radiation therapy for oral cavity cancer. Arch Otolaryngol Head Neck Surg 2003;129: 245-251.
50. Delporte C, O'Connell BC, He X, et al. Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci U S A 1997;94:3268-3273.
51. Epperly MW, Gretton JA, DeFilippi SJ, et al. Modulation of radiation-induced cytokine elevation associated with esophagitis and esophageal stricture by manganese superoxide dismutase-plasmid/liposome (SOD2-PL) gene therapy. Radiat Res 2001;155:2-14.
52. Epperly MW, DeFelippi SJ, Sikora CA, Gretton JA, Kalend A, Greenberger JS. Intratracheal injection A manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation. Gene Ther 2000;7:1011-1018.
53. Chambers MS. Clinical commentary on prophylactic treatment of radiation-induced xerostomia. Arch Otolaryngol Head Neck Surg 2003;129:251-252.
54. LeVeque FG, Montgomery M, Potter D, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124-1131.
55. Fox PC, van der Ven PF, Baum BJ, Mandel ID. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1986;61:243-248.
56. Chambers MS, Toth BB, Payne R, et al. Mutans streptococci and salivary flow rates in cancer patients attending a pain clinic [abstract]. J Dent Res 1997;76:358. Abstract 2755.
57. Chambers M, Martin C, Toth B, et al. Assessment of functional improvement in cancer patients with oral pilocarpine as treatment for anal gesia-induced xerostomia [abstract]. Support Care Cancer 1997;5:164. Abstract 45.
58. Chambers M, Toth B, Martin C, et al. Assessment of salivary flow improvement in cancer patients with oral pilocarpine as treatment for analgesia-induced xerostomia [abstract]. Proc Am Soc Clin Oncol 1997;16:50a. Abstract 174.
59. Scarantino CW, Leveque F, Scott C, et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients [abstract]. Int J Radiat Oncol Biol Phys 2001;51(suppl 1):85-86. Abstract 152.
60. Warde P, Aslanidis J, Kroll B, et al. A phase III placebo controlled trial of oral pilocarpine in patients undergoing radiation therapy for head and neck cancer [abstract]. Int J Radiat Oncol Biol Phys 2001;51(suppl 1): 86. Abstract 153.
61. Cancer Care Ontario Practice Guideline Initiative. Hodson DI, Haines T, Berry M, Johnson M, and the Head and Neck Cancer Disease Site Group. Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients (Practice Guideline Report No. 5-5). Available at: http://www.ccopebc.ca/ guidelines/head/cpg5_5f.html. Accessed February 7, 2003.
62. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-395.
63. Greenspan D, Daniels TE. Effectiveness of pilocarpine in postradiation xerostomia. Cancer 1987;59:1123-1125.
64. Schuller DE, Stevens P, Clausen KP, Olsen J, Gahbauer R, Martin M. Treatment of radiation side effects with oral pilocarpine. J Surg Oncol 1989;42:272-276.
65. Davies AN, Singer J. A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. J Laryngol Otol 1994;108:663-665.
66. Jacobs CD, van der Pas M. A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia. Oncology (Huntingt) 1996;10(suppl):16-20.
67. Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995;49:143-155.
68. Atkinson JC, Baum BJ. Salivary enhancement: current status and future therapies. J Dent Educ 2001;65: 1096-1101.
69. Al-Hashimi I. The management of Sjogren's syndrome in dental practice. J Am Dent Assoc 2001;132:1409-1417.
70. Iga Y, Arisawa H, Ogane N, et al. (±)-cis-2-methylspiro [1,3-oxathiolane-5,3(-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol 1998;78:373-380.
71. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002; 46:748-754.
72. Evoxac™ Capsules (cevimeline hydrochloride). In: Physician's desk reference. 55th ed. Montvale, NJ: Medical Economics Co; 2001:1110-1112.
73. Olsson H, Spak CJ, Axell T. The effect of a chewing gum on salivary secretion, oral mucosal friction, and the feeling of dry mouth in xerostomic patients. Acta Odontol Scand 1991;49:273-279.